Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Phase I Study of Sequential Cord Blood Transplants

04:38 EDT 20th April 2014 | BioPortfolio

Summary

The purpose of this study is to determine the safety of sequential cord blood transplantation (2 cord blood units) for patients who have diseases that are capable of being cured by allogeneic stem cell transplant but do not have a matched family or volunteer unrelated donor.

Description

Eligible patients will receive conditioning therapy with fludarabine 30 mg/m2/day x 6 days, melphalan 100 mg/m2/day x 1 day, rabbit antithymocyte globulin 1.5 mg/kg/day x 4 days. GVHD prophylaxis will consist of cyclosporine starting on day -1 and mycophenolate mofetil starting on day 0. Sequential cord blood units will be infused on Day 0.

Study Design

Allocation: Non-Randomized, Control: Historical Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Lymphoma

Intervention

sequential cord blood transplantation

Location

Massachusetts General Hospital
Boston
Massachusetts
United States
02116

Status

Active, not recruiting

Source

Massachusetts General Hospital

Results (where available)

View Results

Links

Medical and Biotech [MESH] Definitions

Transplantation of STEM CELLS collected from the fetal blood remaining in the UMBILICAL CORD and the PLACENTA after delivery. Included are the HEMATOPOIETIC STEM CELLS.

Blood of the fetus. Exchange of nutrients and waste between the fetal and maternal blood occurs via the PLACENTA. The cord blood is blood contained in the umbilical vessels (UMBILICAL CORD) at the time of delivery.

Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.

Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.

Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.

Clinical Trials [1811 Associated Clinical Trials listed on BioPortfolio]

Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells. PURPOS...

New York Blood Center National Cord Blood Program

Umbilical cord blood is used as a source of hematopoietic stem cells for bone marrow reconstition in patients who would be potential candidates for a bone marrow transplant from an unrelat...

A Phase II Study of Parathyroid Hormone Following Myeloablative Sequential Unrelated Cord Blood Transplantation

The purpose of this study is to determine if the administration of parathyroid hormone after a sequential dual umbilical cord blood transplant can improve the time to engraftment.

Phase I Study of Umbilical Cord Blood Transplantation Followed by Third Party Thymus Transplantation

The objective of this trial is to assess the toxicity of thymus transplantation following unrelated umbilical cord blood transplantation. Emphasis will be placed on adverse events that ar...

Centralized Cord Blood Registry to Facilitate Unrelated Cord Blood Transplantation

The National Marrow Donor Program (NMDP) has established a system for registering, matching, and tracking unrelated donor cord blood units (CBUs) and transplant outcomes. Study subjects a...

PubMed Articles [8771 Associated PubMed Articles listed on BioPortfolio]

New techniques for umbilical cord blood transplantation.

Umbilical cord blood is an alternative hematopoietic stem cell source for treatment of hematological diseases that can be cured by allogeneic hematopoietic stem cell transplantation. Since the first c...

The effect of ABO blood group incompatibility on the outcome of single-unit cord blood transplantation following myeloablative conditioning.

ABO blood group incompatibility between donor and recipient has been associated with transplant outcomes in allogeneic hematopoietic stem cell transplantation. However, its effect on the outcome of co...

Risk of cytomegalovirus infection and disease after umbilical cord blood transplantation in children.

Pediatric data regarding cytomegalovirus (CMV) infections in pediatric patients receiving umbilical cord blood (UCB) transplantation are sparse.

Donor-derived 47, XXY in an unrelated cord blood transplant recipient.

A 65-year-old Japanese male with therapy-related myelodysplastic syndrome was admitted for unrelated cord blood transplantation. A cord blood unit from a male donor was obtained from the Japan Cord Bl...

Risk factors of CMV infection in patients after umbilical cord blood transplantation: a multicenter study in China.

This retrospective study examined risk factors for cytomegalovirus (CMV) infection after umbilical cord blood transplantation (UCBT) and the impact of CMV infection on patient survival.

More From BioPortfolio on "Phase I Study of Sequential Cord Blood Transplants"

Search BioPortfolio:
Advertisement
Advertisement

Searches Linking to this Trial